We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Avantor (AVTR) This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Avantor, Inc. (AVTR - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
Avantor, Inc. is a member of our Medical group, which includes 914 different companies and currently sits at #6 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Avantor, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for AVTR's full-year earnings has moved 2.6% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, AVTR has moved about 20.2% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of 0.1% on a year-to-date basis. As we can see, Avantor, Inc. is performing better than its sector in the calendar year.
Another Medical stock, which has outperformed the sector so far this year, is Johnson & Johnson (JNJ - Free Report) . The stock has returned 23.9% year-to-date.
The consensus estimate for Johnson & Johnson's current year EPS has increased 1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Avantor, Inc. belongs to the Medical Services industry, a group that includes 72 individual stocks and currently sits at #73 in the Zacks Industry Rank. On average, stocks in this group have lost 1% this year, meaning that AVTR is performing better in terms of year-to-date returns.
On the other hand, Johnson & Johnson belongs to the Large Cap Pharmaceuticals industry. This 11-stock industry is currently ranked #234. The industry has moved +9.9% year to date.
Avantor, Inc. and Johnson & Johnson could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
View the Zacks #1 Rank List
Image: Bigstock
Are Medical Stocks Lagging Avantor (AVTR) This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Avantor, Inc. (AVTR - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
Avantor, Inc. is a member of our Medical group, which includes 914 different companies and currently sits at #6 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Avantor, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for AVTR's full-year earnings has moved 2.6% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, AVTR has moved about 20.2% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of 0.1% on a year-to-date basis. As we can see, Avantor, Inc. is performing better than its sector in the calendar year.
Another Medical stock, which has outperformed the sector so far this year, is Johnson & Johnson (JNJ - Free Report) . The stock has returned 23.9% year-to-date.
The consensus estimate for Johnson & Johnson's current year EPS has increased 1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Avantor, Inc. belongs to the Medical Services industry, a group that includes 72 individual stocks and currently sits at #73 in the Zacks Industry Rank. On average, stocks in this group have lost 1% this year, meaning that AVTR is performing better in terms of year-to-date returns.
On the other hand, Johnson & Johnson belongs to the Large Cap Pharmaceuticals industry. This 11-stock industry is currently ranked #234. The industry has moved +9.9% year to date.
Avantor, Inc. and Johnson & Johnson could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.